

6 SEPTEMBER, 2022

Camurus Capital Markets and R&D Day

IVA Conference Center, Wallenbergsalen,
Grev Turegatan 16, Stockholm, Sweden

AGENDA

12:45

Registration & Coffee

13:00

Welcome and introduction

*Lars Frick, Moderator
Fredrik Tiberg, President & CEO*

Camurus today and the path forward – realizing opportunities

Fredrik Tiberg, President & CEO

Establishing market leadership in opioid dependence treatment

*Richard Jameson, CCO
Samantha Nickerson, GM UK & Ireland*

Financial outlook

Jon G. Alonso, CFO

Q&A

14:30

Coffee break

14:45

Buvidal® life cycle management and chronic pain

*Peter Hjälmström, CMO
Lenka Katila, MD, Uppsala University Hospital, Akademiska sjukhuset*

Late-stage pipeline. Bringing octreotide SC depot (CAM2029) to registration in three rare disease indications

*Markus Johnsson, Sr. Dir. Project & Portfolio Management
Diego Ferone, MD, PhD, University of Genoa
Simron Singh, MD, MPH, Prof. University of Toronto*

Closing remarks

Fredrik Tiberg, President & CEO

Q&A

17:00

Meet the team & refreshments

PRESENTERS' BIOGRAPHIES

Fredrik Tiberg, President & Chief Executive Officer, Head of R&D, Camurus

Fredrik Tiberg serves as Camurus President, Chief Executive Officer and Head of R&D since 2003. He holds more than 30 years of experience from the biotechnology and pharmaceutical industry. Prior to joining Camurus, he was CEO of Heptahelix AB, adjunct professor of surface chemistry at Lund University and visiting professor of physical and theoretical chemistry at the University of Oxford. Furthermore, he has more than 120 publications in peer-reviewed scientific journals and is named inventor on more than 400 patents and patent applications. He is Board member of Camurus AB, Camurus Lipid Research Foundation and Amniotics AB and member of the Royal Swedish Academy of Engineering Sciences (IVA). Fredrik holds a M.Sc. in Chemical Engineering from Lund Institute of Technology as well as a Ph.D. and Assoc. Prof. in Physical Chemistry from Lund University.

Jon G. Alonso, Chief Financial Officer, Camurus

Jon U. Garay Alonso was appointed Chief Financial Officer in 2022. He has more than 20 years of experience in Finance and was most recently at Baxter where he for ten years held different Finance Director roles within European businesses. Other previous positions include Vice president Finance & Business Control EMEA at Gambro AB, Nordic Region Finance Director and Unomedical CFO at Convatec – Unomedical A/S and Finance Director Portugal & Iberia and Finance Analysis & Planning Director, at Bristol-Myers Squibb. Jon holds a B.A. by Universidad Comercial de Deusto, an Executive MBA postgraduate program and a General Management Program by IESE Business School.

Richard Jameson, Chief Commercial Officer, Camurus

Richard Jameson holds the position as Camurus Chief Commercial Officer since 2016. He has more than 30 years of global pharmaceutical experience across many disciplines, including leadership roles in sales and marketing, market access, country general management and regional director. Previous experiences include the position as General Manager for UK and the Nordics at Indivior. Prior to that, he led the Reproductive Health unit at Ferring UK and at Schering Plough. Richard holds a B.Sc. (Hons) in Applied Biological Sciences from University of the West of England.

Samantha Nickerson, General Manager UK & Ireland, Camurus

Samantha Nickerson holds the position as Camurus General Manager UK & Ireland since 2020. She has more than 20 years of pharmaceutical and medical devices experience across many disciplines, including leadership roles in sales, marketing and commercial excellence. Before joining Camurus, her most recent position was Business Unit Head for Acute Therapies UK and Ireland at Baxter Healthcare. Prior to that, she led the Haemophilia Sales Organisation at Baxalta (formerly Baxter) and Shire Pharmaceuticals. Samantha holds a B.Sc. in Psychology from University of Surrey and a M.Sc. in Occupational Psychology from Kingston University.

Peter Hjelmström, Chief Medical Officer, Camurus

Peter Hjelmström has been employed at Camurus since 2016 and was appointed Chief Medical Officer in 2020. He has more than 15 years of experience within the pharmaceutical business, including previous positions as Medical Director at Orexo, Head of Clinical Science at Sobi and Medical Affairs Manager at Alexion Pharma. Furthermore, he has more than 40 publications in peer-reviewed scientific journals and is named lead inventor on one patent. Peter holds an MD, Ph.D. and Assoc. Prof. from Karolinska Institute and completed his Postdoctoral fellowship at Yale University.

Lenka Katila, MD, Uppsala University Hospital, Akademiska sjukhuset

Lenka Katila is a Consultant Anesthesiologist and pain physician with a special interest for opioid dependence. She works at Uppsala University Hospital, Akademiska sjukhuset, at a special center at the Addiction clinic for patients with both opioid dependence and chronic pain. She is combining clinical practice with academic research at the Department of Surgical Sciences at Uppsala University. Lenka is auditor at the Swedish Association of Pain Physicians, member of the Swedish Pain Society, Scandinavian Association for the Study of Pain, International Association for Study of Pain, Swedish Addiction Medicine Association and Swedish Endometriosis ARG group. Lenka holds a Medical Degree from Charles University Prague, Medical School in Pilsen, Czech Republic.

Markus Johnsson, Senior Director, Project & Portfolio Management, Camurus

Markus Johnsson holds the position as Senior Director for Camurus Project and Portfolio management. Prior to joining Camurus in 2003, he was a postdoctoral researcher at University of Groningen. After leaving Camurus in 2017 as VP Pharmaceutical & Analytical Development, he took up a position within Project Management at PolyPeptide Laboratories, a global leader in peptide Contract Development & Manufacturing. He re-joined Camurus in 2021. Furthermore, he has more than 30 publications in peer-reviewed scientific journals and is named inventor on more than 400 patents and patent applications. Markus holds a Ph.D. in physical chemistry and M.Sc. in chemistry from Uppsala University.

Diego Ferone, MD, PhD, Endocrinology, IRCCS Policlinico San Martino and Center of Excellence for Biomedical Research, University of Genoa

Diego Ferone is Full Professor of Endocrinology at the Department of Internal Medicine and Medical Specialties of the University of Genoa. He is General Secretary (and past Treasurer) of the Italian Society of Endocrinology, past Secretary of the Italian Society of Andrology and Sexual Medicine, and a member of the Advisory Board of the European Neuroendocrine Tumor Society. In 1999 he was awarded Best Young Researcher by the Italian Society of Endocrinology, as well as Best Italian Researcher in neuroendocrine tumors and multiple endocrine neoplasia in 2010 and the Career Award in 2011. He is the author of more than 200 peer-reviewed articles and 50 book chapters and has presented more than 600 lectures at international and national meetings. Dr. Ferone holds a Ph.D. in Endocrinology and Metabolic Diseases from Università Federico II di Napoli, Naples and a Ph.D. in Neuroendocrinology from Erasmus University of Rotterdam.

Simron Singh, MD, MPH, Sunnybrook Health Science center, Toronto and University of Toronto

Simron Singh is a medical oncologist and affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute. He is co-head of a newly established multi-disciplinary specialized neuroendocrine clinic at Sunnybrook's Odette Cancer Center, one of the first in the region. He is also an assistant professor at the University of Toronto. His research interests include neuroendocrine carcinomas as well as population health and cancer care utilization discrepancies and is the author of more than 90 peer-reviewed articles. Dr. Singh holds a B.Sc. and MD from the University of Alberta, postgraduate training in internal medicine from Queen's University in Kingston and medical oncology from University of Toronto. Additionally, he holds a M.Sc. in public health from Harvard University.

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit [camurus.com](https://www.camurus.com).